Previous studies have shown that the drug activates c-Jun, Akt pathway, epidermal growth factor receptor (EGFR), cancer stem cells enrichment, epithelial-mesenchymal transition (EMT) enhancement and reduces autophagy. Here, AKT1 is linked to cancer.